Celularity Announces Net Sales and Total Revenue Expectations for Fourth Quarter 2023 and Full Year 2023
2024年1月4日 - 2:00AM
Celularity Inc. (Nasdaq: CELU) (the “Company), a biotechnology
company developing allogeneic cell therapies and biomaterial
products, today announced expected net sales of its advance
biomaterial products and biobanking businesses for the fourth
quarter 2023 and the full year 2023 and expected total revenue for
the fourth quarter 2023 and the full year 2023.
For the fourth quarter 2023, the Company expects
net sales of its biomaterial products and biobanking businesses to
be in the range of $11.4 million to $12.1 million and the net sales
percentage growth to be in the range of 176.1% to 193.0% compared
to the fourth quarter 2022.
For the full year 2023, the Company expects net
sales of its biomaterial products and biobanking businesses to be
in the range of $22.06 million to $22.76 million and the net sales
percentage growth to be in the range of 22.7% to 26.6% compared to
the full year 2022.
The Company anticipates that it will announce
actual net sales and actual total revenue for the fourth quarter of
2023 and the full year of 2023 later this year.
“We are particularly encouraged by the growth in
net revenues from our commercial-stage products and services as a
testament to our unique business model, which produces both
cellular and regenerative tools for several clinical indications
such as wound healing and orthopedics. Considering the financial
challenges experienced in the cellular medicine sector in 2023, the
Company is working to maximize access to capital through cash flow
from our manufactured biomaterial products, technical operations
expertise, and cell banking activities. Based on the growth of this
part of our business, we anticipate being able to provide revenue
guidance across our entire business for 2024 in the very near
future,” said Robert J. Hariri, M.D., Ph.D., Chairman, Chief
Executive Officer, and founder.
Forward-Looking Statements
This press release includes “forward-looking
statements” within the meaning of The Private Securities Litigation
Reform Act of 1995, as well as within the meaning of Section 27A of
the Securities Act of 1933, as amended, and Section 21E of the
Securities Exchange Act of 1934, as amended. All statements other
than statements of historical facts are “forward-looking
statements,” including those relating to future events. In some
cases, you can identify forward-looking statements by terminology
such as “anticipate,” “believe,” “can,” “contemplate,” “continue,”
“could,” “estimate,” “expect,” “forecast,” “intends,” “may,”
“might,” “outlook,” “plan,” “possible,” “potential,” “predict,”
“project,” “seek,” “should,” “strive,” “target,” “will,” “would”
and the negative of terms like these or other comparable
terminology, and other words or terms of similar meaning. The
forward-looking statements in this press release include statements
regarding The Company’s ability to sufficiently capitalize itself
through cash flow from its manufactured biomaterial products,
technical operations expertise and cell banking activities, among
others. Many factors could cause actual results to differ
materially from those described in these forward-looking
statements, including but not limited to: the regulatory status of
its biomaterial products; the Company’s ability to develop and
maintain sales and marketing capabilities, whether alone or with
potential future collaborators; the risks associated with the
Company’s current liquidity as well as developments relating to the
Company’s competitors and industry, along with those risk factors
set forth under the caption “Risk Factors” in The Company’s annual
report on Form 10-K filed with the Securities and Exchange
Commission (SEC) on March 31, 2023, and other filings with the SEC.
If any of these risks materialize or underlying assumptions prove
incorrect, actual results could differ materially from the results
implied by these forward-looking statements. There may be
additional risks that The Company does not presently know, or that
The Company currently believes are immaterial, that could also
cause actual results to differ from those contained in the
forward-looking statements. In addition, these forward-looking
statements reflect The Company’s current expectations, plans, or
forecasts of future events and views as of the date of this
communication. Subsequent events and developments could cause
assessments to change. Accordingly, forward-looking statements
should not be relied upon as representing the Company’s views as of
any subsequent date, and the Company undertakes no obligation to
update forward-looking statements to reflect events or
circumstances after the date hereof, whether as a result of new
information, future events or otherwise, except as may be required
under applicable securities laws.
Celularity Investor Contacts:
Carlos Ramirez SVP, Investor RelationsCelularity
Inc.carlos.ramirez@celularity.com
Celularity (NASDAQ:CELU)
過去 株価チャート
から 4 2024 まで 5 2024
Celularity (NASDAQ:CELU)
過去 株価チャート
から 5 2023 まで 5 2024